Kushtrim Kryeziu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kushtrim Kryeziu has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Petra Heffeter
Center for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Borschkegasse 8A, Vienna 1090, Austria
21 shared publications - Walter Berger
Center for Cancer Research, Medical University of Vienna, Borschkegasse 8a, 1090 Vienna, Austria
19 shared publications - Bernhard Klaus Keppler
Institute of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria
8 shared publications - Christian R. Kowol
Institute of Inorganic Chemistry Faculty of Chemistry University of Vienna Vienna Austria
7 shared publications Anita Sveen
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, 0316 Oslo, Norway
6 shared publicationsArild Nesbakken
Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
5 shared publications
Latest Publications
- Open Access
Epigenetic reprogramming by promoter hypomethylation is linked to aberrant gene expression and transcriptomic plasticity in colorectal cancer
Summary: Colorectal cancer (CRC) has high phenotypic plasticity, but regulatory mechanisms of aberrant cell states are not well described. We investigated DNA methylation-based regulation of cancer cell-intrinsic transcriptomic heterogeneity in 1,183 multiregional primary tumor samples, liver metastases and tumor organoids. Most genes with strong methylation-transcriptomic association reflected canonical promoter hypermethylation and expression repression related to the CpG island methylator phenotype (CIMP). However, promoter hypomethylation and overexpression of APOLD1 and ELF5 identified two largely non-overlapping subgroups of canonical CIMP-negative CRCs enriched with stem-like and transit-amplifying cell states. APOLD1 tumors were further highly proliferative while ELF5 tumors were slow-cycling and associated with good survival in early-stage disease. Target genes showed patient-specific expression changes in matched primary-metastasis samples, and ELF5 aberrant metastases showed ex vivo sensitivity to putative targeting of stem cells by PI3K/mTOR inhibition, fetal de-differentiation and transition into non-canonical intestinal states. This implicates focal promoter hypomethylation in phenotypic plasticity in CRC metastasis.
Open AccessEpigenetic reprogramming by promoter hypomethylation is linked to aberrant gene expression and transcriptomic plasticity in colorectal cancer
Summary: Colorectal cancer (CRC) has high phenotypic plasticity, but regulatory mechanisms of aberrant cell states are not well described. We investigated DNA methylation-based regulation of cancer cell-intrinsic transcriptomic heterogeneity in 1,183 multiregional primary tumor samples, liver metastases and tumor organoids. Most genes with strong methylation-transcriptomic association reflected canonical promoter hypermethylation and expression repression related to the CpG island methylator phenotype (CIMP). However, promoter hypomethylation and overexpression of APOLD1 and ELF5 identified two largely non-overlapping subgroups of canonical CIMP-negative CRCs enriched with stem-like and transit-amplifying cell states. APOLD1 tumors were further highly proliferative while ELF5 tumors were slow-cycling and associated with good survival in early-stage disease. Target genes showed patient-specific expression changes in matched primary-metastasis samples, and ELF5 aberrant metastases showed ex vivo sensitivity to putative targeting of stem cells by PI3K/mTOR inhibition, fetal de-differentiation and transition into non-canonical intestinal states. This implicates focal promoter hypomethylation in phenotypic plasticity in CRC metastasis.
- Open Access
- 28 May 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (6) , 102840
Patient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity
- 28 May 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (6) , 102840
Open AccessPatient-derived organoids from metastatic colorectal cancer mirror tumor heterogeneity and predict patient survival and drug sensitivity
- Open Access
- 9 May 2025
- Published by Springer Nature in Research Square
Ex vivo modeling of morphological, molecular and pharmacological tumor heterogeneity of metastatic colorectal cancer
This study reports the establishment and pharmacogenomics analyses of tumor heterogeneity in a living biobank of tumor organoids of 213 liver metastases from 102 patients with metastatic colorectal cancer. Successful organoid culturing reflected poorer chemosensitivity and patient survival. Molecular fidelity was demonstrated in tumor-organoid sample pairs, and multi-modal phenotypes were proposed based on organoid morphologies. Cystic morphology was associated with intestinal stem cell markers and higher drug sensitivities, and solid morphology with markers of cancer cell plasticity and aggressiveness. Potential to identify treatments with less vulnerability to tumor heterogeneity was supported by multi-lesion analyses in 65 patients. Complexity of clinical translation was illustrated by two prospective cases of pharmacogenomics-guided treatment, including successful chemotherapy rechallenge and targeted therapy resistance in cancers with low and high tumor heterogeneity, respectively. All pharmacogenomics data are available as a functional oncology resource and serve as reference for an ongoing intervention trial, supporting the interpretation of ex vivo drug sensitivities into prospective clinical “actionability”.
- 9 May 2025
- Published by Springer Nature in Research Square
Open AccessEx vivo modeling of morphological, molecular and pharmacological tumor heterogeneity of metastatic colorectal cancer
This study reports the establishment and pharmacogenomics analyses of tumor heterogeneity in a living biobank of tumor organoids of 213 liver metastases from 102 patients with metastatic colorectal cancer. Successful organoid culturing reflected poorer chemosensitivity and patient survival. Molecular fidelity was demonstrated in tumor-organoid sample pairs, and multi-modal phenotypes were proposed based on organoid morphologies. Cystic morphology was associated with intestinal stem cell markers and higher drug sensitivities, and solid morphology with markers of cancer cell plasticity and aggressiveness. Potential to identify treatments with less vulnerability to tumor heterogeneity was supported by multi-lesion analyses in 65 patients. Complexity of clinical translation was illustrated by two prospective cases of pharmacogenomics-guided treatment, including successful chemotherapy rechallenge and targeted therapy resistance in cancers with low and high tumor heterogeneity, respectively. All pharmacogenomics data are available as a functional oncology resource and serve as reference for an ongoing intervention trial, supporting the interpretation of ex vivo drug sensitivities into prospective clinical “actionability”.
- Open Access
- 19 May 2023
- Published by Elsevier in Cancer Letters
- Vol. 565, 216237
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
- 19 May 2023
- Published by Elsevier in Cancer Letters
- Vol. 565, 216237
Open AccessA novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
- 1 August 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (15) , 4107-4119
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in colorectal cancer (CRC). Experimental design: We established a platform for ex vivo pharmacogenomic profiling of patient-derived organoids (PDOs) from resected CRC liver metastases. Drug sensitivity testing (n=40 clinically relevant agents) and gene expression profiling were performed of thirty-nine metastases from twenty-two patients. Results: Three drug response clusters were identified among the CRC metastases, based primarily on sensitivities to EGFR and/or MDM2 inhibition, and corresponding with RAS mutations and TP53 activity. Potentially effective therapies, including off-label use of drugs approved for other cancer types, could be nominated for eighteen patients (82%). Antimetabolites and targeted agents lacking a decisive genomic marker had stronger differential activity than most approved chemotherapies. We found limited intra-patient drug sensitivity heterogeneity between PDOs from multiple (2-5) liver metastases from each of ten patients. This was recapitulated at the gene expression level, with a highly proportional degree of transcriptomic and pharmacological variation. One PDO with a multi-drug resistance profile, including resistance to EGFR inhibition in a RAS mutant background, showed sensitivity to MEK plus mTOR/AKT inhibition, corresponding with low-level PTEN expression. Conclusions: Intra-patient inter-metastatic pharmacological heterogeneity was not pronounced and ex vivo drug screening may identify novel treatment options for metastatic CRC. Variation in drug sensitivities was reflected at the transcriptomic level, suggesting potential to develop gene expression-based predictive signatures to guide experimental therapies
- 1 August 2020
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (15) , 4107-4119
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Purpose: Molecular tumor heterogeneity may have important implications for the efficacy of targeted therapies in metastatic cancers. Inter-metastatic heterogeneity of sensitivity to anticancer agents has not been well explored in colorectal cancer (CRC). Experimental design: We established a platform for ex vivo pharmacogenomic profiling of patient-derived organoids (PDOs) from resected CRC liver metastases. Drug sensitivity testing (n=40 clinically relevant agents) and gene expression profiling were performed of thirty-nine metastases from twenty-two patients. Results: Three drug response clusters were identified among the CRC metastases, based primarily on sensitivities to EGFR and/or MDM2 inhibition, and corresponding with RAS mutations and TP53 activity. Potentially effective therapies, including off-label use of drugs approved for other cancer types, could be nominated for eighteen patients (82%). Antimetabolites and targeted agents lacking a decisive genomic marker had stronger differential activity than most approved chemotherapies. We found limited intra-patient drug sensitivity heterogeneity between PDOs from multiple (2-5) liver metastases from each of ten patients. This was recapitulated at the gene expression level, with a highly proportional degree of transcriptomic and pharmacological variation. One PDO with a multi-drug resistance profile, including resistance to EGFR inhibition in a RAS mutant background, showed sensitivity to MEK plus mTOR/AKT inhibition, corresponding with low-level PTEN expression. Conclusions: Intra-patient inter-metastatic pharmacological heterogeneity was not pronounced and ex vivo drug screening may identify novel treatment options for metastatic CRC. Variation in drug sensitivities was reflected at the transcriptomic level, suggesting potential to develop gene expression-based predictive signatures to guide experimental therapies
- Open Access
- 1 April 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1871 (2) , 240-247
Combination therapies with HSP90 inhibitors against colorectal cancer
- 1 April 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Vol. 1871 (2) , 240-247
Open AccessCombination therapies with HSP90 inhibitors against colorectal cancer
- Top Cited PapersOpen Access
- 14 February 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (4) , 794-806
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Purpose: Response to standard oncologic treatment is limited in colorectal cancer. The gene expression–based consensus molecular subtypes (CMS) provide a new paradigm for stratified treatment and drug repurposing; however, drug discovery is currently limited by the lack of translation of CMS to preclinical models. Experimental Design: We analyzed CMS in primary colorectal cancers, cell lines, and patient-derived xenografts (PDX). For classification of preclinical models, we developed an optimized classifier enriched for cancer cell–intrinsic gene expression signals, and performed high-throughput in vitro drug screening (n = 459 drugs) to analyze subtype-specific drug sensitivities. Results: The distinct molecular and clinicopathologic characteristics of each CMS group were validated in a single-hospital series of 409 primary colorectal cancers. The new, cancer cell–adapted classifier was found to perform well in primary tumors, and applied to a panel of 148 cell lines and 32 PDXs, these colorectal cancer models were shown to recapitulate the biology of the CMS groups. Drug screening of 33 cell lines demonstrated subtype-dependent response profiles, confirming strong response to EGFR and HER2 inhibitors in the CMS2 epithelial/canonical group, and revealing strong sensitivity to HSP90 inhibitors in cells with the CMS1 microsatellite instability/immune and CMS4 mesenchymal phenotypes. This association was validated in vitro in additional CMS-predicted cell lines. Combination treatment with 5-fluorouracil and luminespib showed potential to alleviate chemoresistance in a CMS4 PDX model, an effect not seen in a chemosensitive CMS2 PDX model. Conclusions: We provide translation of CMS classification to preclinical models and uncover a potential for targeted treatment repurposing in the chemoresistant CMS4 group. Clin Cancer Res; 24(4); 794–806. ©2017 AACR.
- 14 February 2018
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 24 (4) , 794-806
Top Cited PapersOpen AccessColorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Purpose: Response to standard oncologic treatment is limited in colorectal cancer. The gene expression–based consensus molecular subtypes (CMS) provide a new paradigm for stratified treatment and drug repurposing; however, drug discovery is currently limited by the lack of translation of CMS to preclinical models. Experimental Design: We analyzed CMS in primary colorectal cancers, cell lines, and patient-derived xenografts (PDX). For classification of preclinical models, we developed an optimized classifier enriched for cancer cell–intrinsic gene expression signals, and performed high-throughput in vitro drug screening (n = 459 drugs) to analyze subtype-specific drug sensitivities. Results: The distinct molecular and clinicopathologic characteristics of each CMS group were validated in a single-hospital series of 409 primary colorectal cancers. The new, cancer cell–adapted classifier was found to perform well in primary tumors, and applied to a panel of 148 cell lines and 32 PDXs, these colorectal cancer models were shown to recapitulate the biology of the CMS groups. Drug screening of 33 cell lines demonstrated subtype-dependent response profiles, confirming strong response to EGFR and HER2 inhibitors in the CMS2 epithelial/canonical group, and revealing strong sensitivity to HSP90 inhibitors in cells with the CMS1 microsatellite instability/immune and CMS4 mesenchymal phenotypes. This association was validated in vitro in additional CMS-predicted cell lines. Combination treatment with 5-fluorouracil and luminespib showed potential to alleviate chemoresistance in a CMS4 PDX model, an effect not seen in a chemosensitive CMS2 PDX model. Conclusions: We provide translation of CMS classification to preclinical models and uncover a potential for targeted treatment repurposing in the chemoresistant CMS4 group. Clin Cancer Res; 24(4); 794–806. ©2017 AACR.
- Open Access
- 1 October 2017
- Published by Elsevier in Toxicology Letters
- Vol. 280, S314
Long-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements
- 1 October 2017
- Published by Elsevier in Toxicology Letters
- Vol. 280, S314
Open AccessLong-term exposure of immortalized keratinocytes to arsenic induces EMT, impairs differentiation in organotypic skin models and mimics aspects of human skin derangements
- 1 September 2017
- Published by Elsevier in Cancer Letters
- Vol. 404, 79-88
Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis
- 1 September 2017
- Published by Elsevier in Cancer Letters
- Vol. 404, 79-88
Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis